<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02818452</url>
  </required_header>
  <id_info>
    <org_study_id>PEP-1523</org_study_id>
    <nct_id>NCT02818452</nct_id>
  </id_info>
  <brief_title>Glycemic Impact of Oatmeal Plus OatWellXF28</brief_title>
  <official_title>Affecting the Glycemic Impact of Quaker Instant Oatmeal by Adding OatWell28XF: a Dose-Response Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PepsiCo Global R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DSM Nutritional Products, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>PepsiCo Global R&amp;D</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the effect on glycemic responses of adding&#xD;
      various doses of OatWell28XF to Quaker Instant Oatmeal in order to: 1) describe the&#xD;
      dose-response curve and 2) If possible, identify the minimum level of OatWell28XF which, when&#xD;
      added to a serving of Quaker Instant Oatmeal, would result in a glycemic response at least&#xD;
      20% less than that elicited by a β-glucan-free cereal.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose incremental area under the blood glucose response curve</measure>
    <time_frame>2 hours post consumption</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak rise of blood glucose</measure>
    <time_frame>2 hours post consumption</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose concentrations and increments</measure>
    <time_frame>2 hours post consumption</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak glucose concentration</measure>
    <time_frame>2 hours post consumption</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of decline of glucose</measure>
    <time_frame>2 hours post consumption</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to return to baseline</measure>
    <time_frame>2 hours post consumption</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Glycemic Responses</condition>
  <arm_group>
    <arm_group_label>Oatmeal containing beta-glucan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>27 g oatmeal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oatmeal containing beta-glucan + OatWell28XF Intervention 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>27.72g oatmeal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oatmeal containing beta-glucan + OatWell28XF Intervention 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>28.43g oatmeal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oatmeal containing beta-glucan + OatWell28XF Intervention 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>29.86g oatmeal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oatmeal containing beta-glucan + OatWell28XF Intervention 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>32.72g oatmeal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hot Cereal - Cream of Rice</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20g oatmeal</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oatmeal + OatWell28XF</intervention_name>
    <description>Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence</description>
    <arm_group_label>Oatmeal containing beta-glucan + OatWell28XF Intervention 1</arm_group_label>
    <arm_group_label>Oatmeal containing beta-glucan + OatWell28XF Intervention 2</arm_group_label>
    <arm_group_label>Oatmeal containing beta-glucan + OatWell28XF Intervention 3</arm_group_label>
    <arm_group_label>Oatmeal containing beta-glucan + OatWell28XF Intervention 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oatmeal</intervention_name>
    <arm_group_label>Oatmeal containing beta-glucan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hot cereal</intervention_name>
    <arm_group_label>Hot Cereal - Cream of Rice</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or non-pregnant females, 18-75 years of age, inclusive&#xD;
&#xD;
          -  Body mass index (BMI) ≥ 20.0 and &lt; 35 kg/m² at screening (visit 1).&#xD;
&#xD;
          -  Willing to maintain habitual diet, physical activity pattern, and body weight&#xD;
             throughout the trial and to refrain from smoking for 12hr prior to each visit.&#xD;
&#xD;
          -  Willing to maintain current dietary supplement use throughout the trial. On test days,&#xD;
             subject agrees not to take any dietary supplements until dismissal from the GI labs.&#xD;
             Failure to comply will result in a rescheduled test visit.&#xD;
&#xD;
          -  Normal fasting serum glucose (&lt;7.0mmol/L capillary corresponding to whole blood&#xD;
             glucose &lt;6.3mmol/L).&#xD;
&#xD;
          -  Willing to abstain from alcohol consumption and avoid vigorous physical activity for&#xD;
             24 h prior to all test visits.&#xD;
&#xD;
          -  Absence of health conditions that would prevent fulfillment of study requirements as&#xD;
             judged by the Investigator on the basis of medical history.&#xD;
&#xD;
          -  Understanding the study procedures and willing to provide informed consent to&#xD;
             participate in the study and authorization to release relevant protected health&#xD;
             information to the study investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Failure to meet any one of the inclusion criteria&#xD;
&#xD;
          -  Known history of AIDS, hepatitis, a history or presence of clinically important&#xD;
             endocrine (including Type 1 or Type 2 diabetes mellitus), cardiovascular (including,&#xD;
             but not limited to, atherosclerotic disease, history of myocardial infarction,&#xD;
             peripheral arterial disease, stroke), pulmonary, biliary or GI disorders.&#xD;
&#xD;
          -  Use of medications known to influence carbohydrate metabolism, including, but not&#xD;
             limited to adrenergic blockers, diuretics, thiazolidinediones, metformin and systemic&#xD;
             corticosteroids within 4 weeks of the screening visit, or with any condition which&#xD;
             might, in the opinion of Dr. Wolever, the president of GI Testing, either: 1) make&#xD;
             participation dangerous to the subject or to others, or 2) affect the results.&#xD;
&#xD;
          -  Major trauma or surgical event within 3 months of screening.&#xD;
&#xD;
          -  Unwillingness or inability to comply with the experimental procedures and to follow GI&#xD;
             Labs safety guidelines.&#xD;
&#xD;
          -  Known intolerance, sensitivity or allergy to any ingredients in the study products.&#xD;
&#xD;
          -  Extreme dietary habits, as judged by the Investigator (i.e. Atkins diet, very high&#xD;
             protein diets, etc).&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic blood pressure ≥160 mm Hg or diastolic blood&#xD;
             pressure ≥100 mm Hg as defined by the average blood pressure measured at screening.&#xD;
&#xD;
          -  Change in body weight of &gt;3.5kg within 4 weeks of the screening visit.&#xD;
&#xD;
          -  Presence of any signs or symptoms of an active infection within 5 d prior to any test&#xD;
             visit. If an infection occurs during the study period, test visits should be&#xD;
             rescheduled until all signs and symptoms have resolved and any treatment (i.e.&#xD;
             antibiotic therapy) has been completed at least 5 d prior to each test visit.&#xD;
&#xD;
          -  History of cancer in the prior two years, except for non-melanoma skin cancer.&#xD;
&#xD;
          -  Recent history (within 12 months of screening) or strong potential for alcohol or&#xD;
             substance abuse. Alcohol abuse is defined as &gt; 14 drinks per week (1 drink=12 oz beer,&#xD;
             5 oz wine, or 1.5 oz distilled spirits).&#xD;
&#xD;
          -  Exposure to any non-registered drug product within 30 d prior to screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Wolever, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GI Laboratories</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GI Labs</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>June 14, 2016</study_first_submitted>
  <study_first_submitted_qc>June 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2016</study_first_posted>
  <last_update_submitted>December 5, 2016</last_update_submitted>
  <last_update_submitted_qc>December 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

